Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1 - PubMed (original) (raw)
. 2004 Jan 15;189(2):312-21.
doi: 10.1086/380098. Epub 2004 Jan 7.
Affiliations
- PMID: 14722897
- DOI: 10.1086/380098
Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1
Steven G Deeks et al. J Infect Dis. 2004.
Abstract
Antiretroviral (ARV)-treated patients often maintain low to moderate levels of viremia, despite the emergence of drug-resistant human immunodeficiency virus (HIV). We studied host and viral factors that may contribute to the control of viral replication in a cohort of 189 adults. Among ARV-treated patients with detectable viremia, there was a bell-shaped relationship between Gag-specific CD4+ T cell responses and viremia, with the highest cellular immune responses observed in patients with plasma HIV RNA levels of 1000-10,000 copies/mL. In contrast, there was a negative association between Gag-specific CD4+ T cell responses and viremia among ARV-untreated individuals with wild-type HIV. Strong cellular immune responses among individuals with drug-resistant HIV predicted subsequent lack of virological progression. Finally, there was a positive correlation between replicative capacity and viremia. Collectively, these data suggest that the selection of drug-resistance mutations may reduce the pathogenic potential of HIV, which leads to a balanced state of enhanced cellular immunity and low-level viremia.
Similar articles
- Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
Oxenius A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, García F, Hirschel B, McLean A, Phillips RE. Oxenius A, et al. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52. doi: 10.1073/pnas.202372199. Epub 2002 Oct 7. Proc Natl Acad Sci U S A. 2002. PMID: 12370434 Free PMC article. Clinical Trial. - CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients.
Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, McCutchan F, Njovu L, Geis S, Hoffmann O, Maboko L, Williamson C, Birx D, Meyerhans A, Cox J, Hoelscher M. Geldmacher C, et al. J Virol. 2007 Mar;81(5):2440-8. doi: 10.1128/JVI.01847-06. Epub 2006 Dec 20. J Virol. 2007. PMID: 17182686 Free PMC article. - Immune control of HIV-1 after early treatment of acute infection.
Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D'Aquila RT, Goulder PJ, Walker BD. Rosenberg ES, et al. Nature. 2000 Sep 28;407(6803):523-6. doi: 10.1038/35035103. Nature. 2000. PMID: 11029005 Clinical Trial. - The value of preserving HIV-specific immune responses.
Kaufmann DE, Rosenberg ES. Kaufmann DE, et al. J HIV Ther. 2003 Feb;8(1):19-25. J HIV Ther. 2003. PMID: 12840711 Review. - Control of HIV-1 replication in elite suppressors.
Blankson JN. Blankson JN. Discov Med. 2010 Mar;9(46):261-6. Discov Med. 2010. PMID: 20350494 Review.
Cited by
- CD4+ T cells from HIV-1-infected patients recognize wild-type and mutant human immunodeficiency virus-1 protease epitopes.
Muller NG, Alencar R, Jamal L, Hammer J, Sidney J, Sette A, Brindeiro RM, Kalil J, Cunha-Neto E, Moraes SL. Muller NG, et al. Clin Exp Immunol. 2011 Apr;164(1):90-9. doi: 10.1111/j.1365-2249.2011.04319.x. Epub 2011 Feb 24. Clin Exp Immunol. 2011. PMID: 21352200 Free PMC article. - HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels.
Jordan MR, Winsett J, Tiro A, Bau V, Berbara RS, Rowley C, Bellosillo N, Wanke C, Coakley EP. Jordan MR, et al. World J AIDS. 2013 Jun;3(2):71-78. doi: 10.4236/wja.2013.32010. World J AIDS. 2013. PMID: 25664219 Free PMC article. - Control of M184V HIV-1 mutants by CD8 T-cell responses.
Vollbrecht T, Eberle J, Roider J, Bühler S, Stirner R, Henrich N, Seybold U, Bogner JR, Draenert R. Vollbrecht T, et al. Med Microbiol Immunol. 2012 May;201(2):201-11. doi: 10.1007/s00430-011-0222-1. Epub 2011 Dec 27. Med Microbiol Immunol. 2012. PMID: 22200907 - Tackling HIV and AIDS: contributions by non-human primate models.
Van Rompay KKA. Van Rompay KKA. Lab Anim (NY). 2017 May 22;46(6):259-270. doi: 10.1038/laban.1279. Lab Anim (NY). 2017. PMID: 28530684 - Treatment of pediatric HIV infection.
d'Oulx EA, Chiappini E, de Martino M, Tovo PA. d'Oulx EA, et al. Curr Infect Dis Rep. 2007 Sep;9(5):425-33. doi: 10.1007/s11908-007-0065-5. Curr Infect Dis Rep. 2007. PMID: 17880854
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials